A revolution in disease treatment

Halia Therapeutics, a clinical-stage biopharma company, is creating a new class of small molecule medications to combat inflammation. Its drug candidates are the first to target the protein NEK7 to inhibit NLRP3 inflammasome activity, a key cause of inflammation linked to various diseases. The lead candidate, HT-6184, is undergoing phase II studies for treating inflammatory pain and cancer. Also, Halia is collaborating to use AI in developing an Alzheimer’s drug, HT-4253.